VIR•benzinga•
Goldman Sachs Maintains Buy on Vir Biotechnology, Lowers Price Target to $21
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga